120 Recruiting Trials

Clinical Trials
for Cancer in Rhode Island

120 clinical trials for Cancer are currently recruiting participants at study sites in Rhode Island. Study-related care is provided at no cost.

120
Recruiting trials
46
Study sites
4
Cities
62
Industry-sponsored
50
Phase 2
52
Phase 3

Cancer clinical trials in Rhode Island: what to expect

Cancer is the single largest area of clinical research, and nearly every recruiting cancer trial is written for one cancer type at one stage. Most test a new drug or combination against the current standard treatment: targeted medicines matched to a mutation found in the tumor, immunotherapies that help the immune system recognize cancer cells, antibody-drug conjugates and cell therapies. Others study surgery and radiation techniques, ways to reduce side effects, and screening or prevention in people at higher risk.

In Rhode Island, recruiting cancer studies are concentrated in Providence, Westerly, Warwick and East Providence. 62 of the 120 are run by a drug or device company, which usually means a larger study with travel reimbursement; the rest are academic or hospital-led.

Who cancer trials usually look for

Every listing names the cancer type and stage it enrolls, and most also state how many earlier treatments you may have had: some are for people newly diagnosed, many are for cancer that has come back or spread after a first treatment stopped working. Targeted-therapy trials require a specific result on tumor testing, which the site can arrange if it has not been done. Trials generally ask that you are well enough for daily activity (a "performance status" the doctor scores), that blood counts and liver and kidney function are adequate, and that a few weeks have passed since your last treatment.

Having advanced or metastatic cancer does not rule you out. A large share of recruiting trials are designed specifically for it.

What taking part involves

Screening reviews your pathology and scans, often with new blood work and sometimes a fresh biopsy. Treatment then follows a cycle, typically every two or three weeks, with scans every six to twelve weeks to measure the response. Early-phase trials have more frequent visits at the start. The study drug and study-specific tests are provided at no cost; standard care that you would receive anyway is usually billed to insurance as normal. A placebo on its own is rare in cancer trials: when there is one, it is added to the standard treatment, and the consent form says so.

Questions worth asking the study team

Whether the trial is randomized and what the comparison treatment is; what happens if the cancer grows during the study; whether you can keep receiving the drug afterward if it is working; how the trial fits with the plan your own oncologist has suggested; and what travel or lodging support is offered. Your oncologist can also refer you directly.

Showing 20 of 120 recruiting Cancer trials in Rhode Island

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
PHASE2 Little Rock, Arkansas +4 sites NCT05997017
This trial is looking for women with advanced or recurrent endometrioid endometrial cancer to test a combination of two medications. Participants must have measurable disease and meet certain health criteria to join the study.
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
PHASE3 Birmingham, Alabama +4 sites NCT06901531
This trial is looking for adults with advanced stomach or gastroesophageal junction cancer. Participants will receive a combination of zolbetuximab, pembrolizumab, and chemotherapy, or a placebo with pembrolizumab and chemotherapy to see how well it works.
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT05827081
This trial is looking for adults with early breast cancer that is hormone receptor positive and HER2 negative. If you join, you will receive ribociclib along with standard hormone therapy to see how effective this combination is.
Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT06058377
This trial is looking for women with hormone receptor positive, HER2 negative stage II-III breast cancer. Participants will receive standard chemotherapy along with an immunotherapy drug called durvalumab to see if it helps prevent cancer from coming back.
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
PHASE3 Phoenix, Arizona +4 sites NCT06952803
This trial is looking for men with high-risk prostate cancer who have a specific gene mutation. Participants will receive either the drug Saruparib or a placebo along with standard radiation and hormone therapy to see how well they can avoid cancer spread.
Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
PHASE2 Goodyear, Arizona +4 sites NCT04613596
This trial is looking for patients with advanced non-small cell lung cancer who have a specific mutation. Participants will receive treatments to see how well they work.
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
PHASE3 Birmingham, Alabama +4 sites NCT05633654
This trial is looking for adults with triple negative breast cancer that remains after surgery and treatment. Participants will receive an experimental treatment combining two medications after recovery from surgery.
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
PHASE3 Birmingham, Alabama +4 sites NCT05774951
This trial is looking for people with early breast cancer who have completed at least 2 years of standard treatment. Participants will receive camizestrant to see if it helps improve their outcomes compared to standard therapy.
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
PHASE3 Birmingham, Alabama +4 sites NCT06824467
This trial is looking for women with certain types of ovarian cancer who have had previous chemotherapy. Participants will receive a treatment to see if it helps them live longer without their cancer worsening.
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
PHASE3 Mobile, Alabama +4 sites NCT06952504
This trial is looking for people with advanced or recurring endometrial cancer that has specific characteristics. Participants will receive a combination of two medicines, sacituzumab tirumotecan and pembrolizumab, to see if it helps them live longer or keeps the cancer from worsening.
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
PHASE3 Tucson, Arizona +4 sites NCT06989112
This trial is looking for adults with a specific type of endometrial cancer. Participants will receive either a combination of two new treatments or a standard chemotherapy and immunotherapy to see how well they work.
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
PHASE3 Birmingham, Alabama +4 sites NCT07216703
This trial is looking for women with cervical cancer that has spread and cannot be cured with surgery or radiation. Participants will receive a combination of study medicines to help learn how effective and safe they are.
Recruiting
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis
PHASE3 Jonesboro, Arkansas +4 sites NCT07578116
This trial is looking for patients with HER2-positive breast cancer that has spread to other parts of the body. Participants will receive standard drug treatment and may also undergo surgery and radiation therapy.
Recruiting
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
PHASE3 Chandler, Arizona +4 sites NCT06377852
This trial is looking for older patients with metastatic breast cancer to test different dosing strategies for two medications. Participants will help researchers understand how well these strategies work and which might be better tolerated.
Recruiting
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
PHASE3 Mobile, Alabama +4 sites NCT07228832
This trial is looking for patients with metastatic colorectal cancer who have not received any previous treatment. Participants will receive either Ivonescimab or Bevacizumab combined with chemotherapy as their first treatment.
Recruiting
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
PHASE3 Phoenix, Arizona +4 sites NCT06876714
This trial is looking for adults with HER2-positive breast cancer who have no residual invasive disease after chemotherapy. Participants will receive either 6 or 12 months of HER2-targeted medications to see which duration works best.
Recruiting
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
PHASE3 Birmingham, Alabama +4 sites NCT06079671
This trial is looking for women with high-risk locally advanced cervical cancer who have not progressed after treatment. Participants will receive volrustomig to see how well it works and what side effects it may cause.
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
PHASE3 Daphne, Alabama +4 sites NCT06103864
This trial is looking for patients with a specific type of breast cancer that is not treatable by surgery. Participants will receive a treatment called Dato-DXd, with or without another drug, or a standard chemotherapy treatment.
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
PHASE3 Mobile, Alabama +4 sites NCT06627647
This trial is looking for adults with a specific type of lung cancer that has spread and has specific characteristics. Participants will receive one of two treatments combined with chemotherapy as part of their first treatment plan.
Recruiting

Where the Cancer studies are in Rhode Island

  • Rhode Island Hospital, Providence27 trials
  • Smilow Cancer Hospital Care Center - Westerly, Westerly21 trials
  • Research Site, Providence19 trials
  • Women and Infants Hospital, Providence17 trials
  • Women & Infants Hospital, Providence5 trials
  • Kent Hospital, Warwick4 trials

Counts are recruiting studies listing at least one site in Rhode Island, from ClinicalTrials.gov, refreshed every two days.

Cancer clinical trials in Rhode Island: common questions

How many Cancer clinical trials are recruiting in Rhode Island?
TrialFinder currently lists 120 recruiting Cancer clinical trials with study sites in Rhode Island. Results are updated regularly from ClinicalTrials.gov, the official U.S. registry of clinical studies.
Where are Cancer clinical trials located in Rhode Island?
Sites for these Cancer trials are spread across Rhode Island. Open any trial to see its full list of participating locations and contact details.
Do I need insurance to join a Cancer clinical trial in Rhode Island?
No. Study-related care is covered by the trial sponsor at no cost to participants, including the study treatment, required lab tests and study visits. Many Cancer trials in Rhode Island also compensate participants for time and travel. Health insurance is not required to search or enroll.
How do I qualify for a Cancer clinical trial in Rhode Island?
Each study sets its own criteria based on age, Cancer diagnosis details, prior treatments, current medications and general health. The fastest way to find out is to contact a research site directly — most will pre-screen you by phone in 10 to 15 minutes at no charge. You can also create a free TrialFinder profile to be matched automatically.
Will I get a placebo instead of cancer treatment?
Almost never. Cancer trials compare a new treatment with the current standard treatment, or add the study drug to standard treatment. When a placebo is used it is on top of standard care, and the consent form states this before you decide.
Can I join a cancer trial if my cancer has spread?
Yes. Many recruiting cancer trials are written for advanced or metastatic disease, including people whose earlier treatments have stopped working. The listing states the stage and prior treatments it accepts.
Do I have to stop my current cancer treatment to join a trial?
It depends on the trial. Some enroll people whose current treatment has stopped working, some add the study drug to the treatment you are on, and some are for people who have not started treatment yet. Ask the study team before changing anything.
Are Clinical Trials Safe? What Patients Should Know
How clinical trial safety works — phases, IRB oversight, informed consent, and your right to withdraw — plus the real risks and questions to ask.
How to Know If You Qualify for a Clinical Trial
Every trial has eligibility criteria based on diagnosis, age, and medical history. Here's how to tell if you qualify — and what to do if you're not sure.
Clinical Trials Without Insurance: What You Need to Know
Clinical trials cover the cost of study-related care, making them one of the few ways to access treatment without health insurance. Here's what's covered.
All guides →

Check Your Eligibility

Create a free profile and our AI will match you to Cancer trials near you in Rhode Island.

Get Matched — Free
No insurance required

Breast cancer trials test new chemotherapy regimens, immunotherapy combinations, targeted therapies, and early-detection methods across all stages of breast cancer.

All Cancer trials →